BNXT Stock Overview
Engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BioNxt Solutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.30 |
| 52 Week High | CA$0.75 |
| 52 Week Low | CA$0.17 |
| Beta | 0.55 |
| 11 Month Change | -21.05% |
| 3 Month Change | -40.00% |
| 1 Year Change | -36.17% |
| 33 Year Change | -83.33% |
| 5 Year Change | n/a |
| Change since IPO | -70.00% |
Recent News & Updates
Shareholder Returns
| BNXT | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -11.8% | 1.7% | 0.7% |
| 1Y | -36.2% | 35.5% | 10.1% |
Return vs Industry: BNXT underperformed the Canadian Pharmaceuticals industry which returned 39.3% over the past year.
Return vs Market: BNXT underperformed the Canadian Market which returned 11.3% over the past year.
Price Volatility
| BNXT volatility | |
|---|---|
| BNXT Average Weekly Movement | 19.7% |
| Pharmaceuticals Industry Average Movement | 12.7% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 16.8% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: BNXT's share price has been volatile over the past 3 months.
Volatility Over Time: BNXT's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Hugh A. Rogers | www.bionxt.com |
BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains.
BioNxt Solutions Inc. Fundamentals Summary
| BNXT fundamental statistics | |
|---|---|
| Market cap | CA$35.37m |
| Earnings (TTM) | -CA$7.80m |
| Revenue (TTM) | CA$206.74k |
160.4x
P/S Ratio-4.3x
P/E RatioIs BNXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNXT income statement (TTM) | |
|---|---|
| Revenue | CA$206.74k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$206.74k |
| Other Expenses | CA$8.01m |
| Earnings | -CA$7.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.071 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,773.05% |
| Debt/Equity Ratio | -83.5% |
How did BNXT perform over the long term?
See historical performance and comparison